Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Canerpaturev + Ipilimumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Canerpaturev||HSV-1 HF10|herpes simplex virus type 1 HF10|HF10||Canerpaturev (HF10) is a spontaneous herpes simplex virus (HSV) type I mutant variant, which is capable of infecting and lysing tumor cells, and may also lead to non-infected tumor cell death by increasing host immune response (PMID: 31193737).|
|Ipilimumab||Yervoy||BMS-734016||CTLA4 Antibody 17 Immune Checkpoint Inhibitor 94||Yervoy (ipilimumab) is an antibody that binds to cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), causing increased T-cell activation (PMID: 28891423). Yervoy (ipilimumab) is FDA approved for use in patients with metastatic melanoma, including patients 12 years or older, and in combination with Opdivo (nivolumab) for intermediate or poor-risk renal cell carcinoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (including patients 12 years or older), hepatocellular carcinoma previously treated with Nexavar (sorafenib), in combination with Opdivo (nivolumab) as first-line therapy in patients with PD-L1-positive (>=1%) metastatic non-small cell lung cancer without EGFR or ALK alterations, and in combination with Opdivo (nivolumab) and platinum-based chemotherapy as first-line therapy in patients with metastatic or recurrent non-small cell lung cancer without EGFR or ALK alterations (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02272855||Phase II||Canerpaturev + Ipilimumab||A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic Melanoma||Completed|